Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358821 · ClinicalTrials.gov registry record · Phase 2
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT05358821 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 69 participants.
The verdict
NCT05358821, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
Interventions
- DRUG Placebo
- DRUG SAGE-718
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2024-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05358821
The ClinicalTrials.gov registry entry for NCT05358821 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05358821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05358821 about?
NCT05358821 is a clinical study titled "28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease". The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
What is the current status of trial NCT05358821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2022-05-26. Estimated completion is 2024-04-10.
What interventions are being tested in trial NCT05358821?
The interventions under investigation include: Placebo (DRUG), SAGE-718 (DRUG).
Who is sponsoring clinical trial NCT05358821?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.